Clinical Trial Update: Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating prefrontal glutamatergic modulation with N-acetylcysteine (NAC) and mindfulness-based cognitive therapy (MBCT) for depres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Mindfulness-based cognitive therapy
• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: University of Cincinnati | Conditions: Mild Depression | Phase 3 | Status: RECRUITING